Cocaine dependence is an important problem without any effective pharmacological treatment. Some preclinical studies have suggested that cannabidiol (CBD), a component of the Cannabis sativa plant, could be useful for the treatment of cocaine use disorders.
Aims:
This work aims to evaluate the ability of CBD to reduce priming- and stress-induced reinstatement of the conditioned place preference (CPP) induced by cocaine.
Methods:
Young adult CD-1 male mice were allocated to 10 groups (n = 12/group), conditioned with cocaine (10 mg/kg) and exposed to extinction of CPP (two sessions per week). When extinction was achieved, each group received the corresponding treatment before the reinstatement test. In experiment 1, six groups were used: vehicle+saline (Veh+Sal), 5 mg/kg cocaine alone (Veh+Coc) or with CBD 30 or 60 mg/kg (CBD30+Coc, CBD60+Coc) and CBD alone (CBD30+Sal, CBD60+Sal). In experiment 2, four groups were used: exploration (Veh+Expl), social defeat (Veh+SD) and social defeat with CBD (CBD30+SD and CBD60+SD). Furthermore, the relative gene expression of the dopamine transporter (DAT) in the ventral tegmental area was measured.
Results:
All mice acquired cocaine CPP and extinguished it after three or four weeks. Only the groups treated with cocaine priming (Veh+Coc) or exposed to social defeat (Veh+SD) showed reinstatement of CPP. Interestingly, CBD itself did not induce reinstatement and blocked the reinstating effects of cocaine priming and social defeat. Furthermore, cocaine priming increased DAT gene expression in the ventral tegmental area and CBD completely reversed this effect.
Conclusion:
These results suggest that CBD could reduce reinstatement to cocaine seeking after a period of abstinence.
AhrensJDemirRLeuwerM, et al. (2009) The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function. Pharmacology83: 217–222.
2.
AnanthMHetelekidesEMHamiltonJ . (2019) Dopamine D4 receptor gene expression plays important role in extinction and reinstatement of cocaine-seeking behavior in mice. Behav Brain Res365: 1–6.
3.
ArenasMCMateos-GarcíaAManzanedoC, et al. (2016) Topiramate increases the rewarding properties of cocaine in young-adult mice limiting its clinical usefulness. Psychopharmacology233: 3849–3859.
4.
BabalonisSHaneyMMalcolmRJ, et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend172: 9–13.
5.
BahiABoyerFChandrasekarV, et al. (2008) Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats. Psychopharmacology199: 169–182.
6.
BeckerJB (2016) Sex differences in addiction. Dialogues Clin Neurosci18: 395–402.
7.
BeumingTKniazeffJBergmannML, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci11: 780–789.
8.
BilbaoARiekerCCannellaN, et al. (2014) CREB activity in dopamine D1 receptor expressing neurons regulates cocaine-induced behavioral effects. Front Behav Neurosci8: 212.
9.
BisognoTHanusLDe PetrocellisL, et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol134: 845–852.
10.
BlessingEMSteenkampMMManzanaresJ, et al. (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics12: 825–836.
11.
BoutrelB (2008) A neuropeptide-centric view of psychostimulant addiction. Br J Pharmacol154: 343–357.
12.
BrownTEForquerMRHardingJW, et al. (2008) Increase in matrix metalloproteinase-9 levels in the rat medial prefrontal cortex after cocaine reinstatement of conditioned place preference. Synapse62: 886–889.
13.
Calpe-LópezCGarcía-PardoMPAguilarMA (2019) Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. Molecules24: 2583.
14.
CamposACGuimarãesFS (2008) Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology199: 223–230.
15.
CrippaJAGuimarãesFSCamposAC, et al. (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol9: 2009.
16.
de CarvalhoCRTakahashiRN (2017) Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats. Addict Biol22: 742–751.
17.
DeianaSWatanabeAYamasakiY, et al. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology219: 859–873.
18.
GalajEBiGHYangHJ, et al. (2020) Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms. Neuropharmacology167: 107740.
19.
García-PardoMPLLansolaMFelipoV, et al. (2020) Blockade of nitric oxide signalling promotes resilience to the effects of social defeat stress on the conditioned rewarding properties of MDMA in mice. Nitric Oxide98: 29–32.
20.
Gonzalez-CuevasGMartin-FardonRKerrTM, et al. (2018) Unique treatment potential of cannabidiol for the prevention of relapse to drug use: Preclinical proof of principle. Neuropsychopharmacology43: 2036–2045.
21.
HartmannALisboaSFSonegoAB, et al. (2019) Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry94: 109637.
22.
HayGLBaraczSJEverettNA, et al. (2018) Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. J Psychopharmacol32: 1369–1378.
23.
HayakawaKMishimaKHazekawaM, et al. (2008) Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res1188: 157–164.
24.
HurdYL (2017) Cannabidiol: Swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic. Trends Neurosci40: 124–127.
25.
Ibeas BihCChenTNunnAV, et al. (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics12: 699–730.
26.
IfflandKGrotenhermenF (2017) An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res2: 139–154.
27.
IzzoABorrelliFCapassoR, et al. (2009) Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol Sci30: 515–527.
28.
KampmanKM (2019) The treatment of cocaine use disorder. Sci Adv5: eaax1532.
29.
Karimi-HaghighiSHaghparastA (2018) Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats. Prog Neuropsychopharmacol Biol Psychiatry82: 307–313.
30.
Karimi-HaghighiSDargahiLHaghparastA (2020) Cannabidiol modulates the expression of neuroinflammatory factors in stress- and drug-induced reinstatement of methamphetamine in extinguished rats. Addict Biol25: e12740.
31.
KathmannMFlauKRedmerA, et al. (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol372: 354–361.
32.
KatsidoniVAnagnostouIPanagisG (2013) Cannabidiol inhibits the reward-facilitating effect of morphine: Involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol2: 286–296.
33.
KokaneSSPerrottiLI (2020) Sex differences and the role of estradiol in mesolimbic reward circuits and vulnerability to cocaine and opiate addiction. Front Behav Neurosci14: 74.
34.
KoobGFVolkowND (2016) Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry3: 760–773.
35.
LaprairieRBBagherAMKellyME, et al. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol172: 4790–805.
36.
LaunASSongZH (2017) GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem Biophys Res Commun490: 17–21.
37.
LewekeFMPiomelliDPahlischF, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry2: e94.
38.
LinaresIMZuardiAWPereiraLC, et al. (2019) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry41: 9–14.
39.
LivakKJSchmittgenTD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods25: 402–408.
40.
LucasCJGalettisPSchneiderJ (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol84: 2477–2482.
41.
LujánMÁCantacorpsLValverdeO (2020) The pharmacological reduction of hippocampal neurogenesis attenuates the protective effects of cannabidiol on cocaine voluntary intake. Addict Biol25: e12778.
42.
LujánMÁCastro-ZavalaAAlegre-ZuranoL, et al. (2018) Repeated cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. Neuropharmacology143: 163–175.
43.
MahgoubMKeun-HangSYSydorenkoV, et al. (2013) Effects of cannabidiol on the function of α7-nicotinic acetylcholine receptors. Eur J Pharmacol720: 310–319.
44.
MahmudAGallantSSedkiF, et al. (2017) Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats. J Psychopharmacol31: 96–104.
45.
MaldonadoCRodríguez-AriasMCastilloA, et al. (2006) Gamma-hydroxybutyric acid affects the acquisition and reinstatement of cocaine-induced conditioned place preference in mice. Behav Pharmacol17: 1191.
46.
MaldonadoCRodríguez-AriasMCastilloA, et al. (2007) Effect of memantine and CNQX in the acquisition, expression and reinstatement of cocaine-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry31 :932–939.
47.
MantschJRBakerDAFunkD, et al. (2016) Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. Neuropsychopharmacol41: 335–356.
48.
MechoulamRHanusL (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids121: 35–43.
49.
MechoulamRParkerLAGallilyR (2002) Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol42(S1):11S–19S.
NavarreteFAracil-FernándezAManzanaresJ (2018) Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal. Br J Pharmacol175: 2676–2688.
52.
NirenbergMJChanJVaughanRA, et al. (1997) Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci17: 5255–5262.
PandolfoPSilveirinhaVdos Santos-RodriguesA, et al. (2011) Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol655: 38–45.
55.
ParkerLABurtonPSorgeRE, et al. (2004) Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology175: 360–366.
56.
PaxinosGFranklinKBJ (2001) The Mouse Brain in Stereotaxic Coordinates. New York: Academic Press; Harcourt Science and Technology Company.
57.
PertweeRG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol153: 199–215.
58.
PisantiSMalfitanoAMCiagliaE, et al. (2017) Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther175: 133–150.
59.
Quinones-JenabVJenabS (2012) Influence of sex differences and gonadal hormones on cocaine addiction. ILAR J53: 14–22.
60.
Ribeiro Do CoutoBAguilarMALluchJ, et al. (2009) Social experiences affect reinstatement of cocaine-induced place preference in mice. Psychopharmacology207: 485–498.
61.
Rodríguez-AriasMMiñarroJAguilarMA, et al. (1998) Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice. Eur Neuropsychopharmacol8: 95–103.
62.
Rodríguez-AriasMRoger-SánchezCVilanovaI, et al. (2016) Effects of cannabinoid exposure during adolescence on the conditioned rewarding effects of WIN 55212-2 and cocaine in mice: Influence of the novelty-seeking trait. Neural Plast2016: 6481862.
63.
RothwellPEKourrichSThomasMJ (2011) Synaptic adaptations in the nucleus accumbens caused by experiences linked to relapse. Biol Psychiatry69: 1124–1126.
64.
RussoEBBurnettAHallB, et al. (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res30: 1037–1043.
65.
RybergELarssonNSjögrenS, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol152: 1092–1101.
66.
SchmidtHDPierceRC (2006) Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat. Neuroscience142: 451–461.
67.
SchmidtHDAndersonSMFamousKR, et al. (2005) Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. Eur J Pharmacol526: 65–76.
68.
SeemanP (2016) Cannabidiol is a partial agonist at dopamine d2high receptors, predicting its antipsychotic clinical dose. Transl Psychiatry6: e920.
69.
SicilianoCAFordahlSCJonesSR (2016) Cocaine self-administration produces long-lasting alterations in dopamine transporter responses to cocaine. J Neurosci36: 7807–7816.
70.
StraikerADvorakovaMZimmowitchA, et al. (2018) Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Mol Pharmacol94: 743–748.
71.
TaylorLGidalBBlakeyG, et al. (2018) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs32: 1053–1067.
72.
ThamMYilmazOAlaverdashviliM, et al. (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol176: 1455–1469.
73.
TitomanlioFManzanedoCRodríguez-AriasM, et al. (2013) Rhodiola rosea impairs acquisition and expression of conditioned place preference induced by cocaine. Evid Based Complement Alternat Med2013: 697632.
74.
TornatzkyWMiczekKA (1993) Long-term impairment of autonomic circadian rhythms after brief intermittent social stress. Physiol Behav53: 983–993.
75.
TurnaJSyanSKFreyBN, et al. (2019) Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: A systematic review. Alcohol Clin Exp Res43: 550–563.
76.
VermaV (2015) Classic studies on the interaction of cocaine and the dopamine transporter. Clin Psychopharmacol Neurosci13: 227–238.
77.
Viudez-MartínezAGarcía-GutiérrezMSFraguas-SánchezAI, et al. (2018a) Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. Br J Pharmacol175: 3369–3378.
78.
Viudez-MartínezAGarcía-GutiérrezMSNavarrónCM, et al. (2018b) Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol23: 154–164.
79.
Viudez-MartínezAGarcía-GutiérrezMSMedrano-RelinqueJ, et al. (2019) Cannabidiol does not display drug abuse potential in mice behavior. Acta Pharmacol Sin40: 358–364.
80.
Viudez-MartínezAGarcía-GutiérrezMSManzanaresJ (2020) Gender differences in the effects of cannabidiol on ethanol binge drinking in mice. Addict Biol25: e12765.
81.
YouI-JHongS-IMaS-X, et al. (2019) Transient receptor potential vanilloid 1 mediates cocaine reinstatement via the D1 dopamine receptor in the nucleus accumbens. J Psychopharmacol33: 1491–1500.
82.
ZlebnikNECheerJF (2016) Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?Annu Rev Neurosci39: 1–17.
83.
ZuardiAWRodriguesNPSilvaAL, et al. (2017) Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol8: 259.
